Gordon Sangster to join Codexis as Chief Financial Officer

He has held CFO positions at public and private life science companies for the last 14 years

Codexis, a developer of biocatalysts for the pharmaceutical and fine chemical industries, has appointed Gordon Sangster as Senior Vice President and Chief Financial Officer.

Sangster joins the company on 18 August and will report to Chief Executive John Nicols.

Prior to joining Codexis, Sangster has been Chief Financial Officer at multiple public and private life science companies for the last 14 years.

From 2011 to July 2014, Sangster was Chief Financial Officer of Nitinol Devices & Components, a private medical device manufacturer. He has also been CFO at medical device companies ITC Nexus-Dx; Micrus Endovascular; HemoSense; and at biotech company AP Pharma.

You may also like

Ingredients

Nestlé tackles phenylketonuria with Codexis enzyme

Codexis announces that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialisation of the orally delivered enzyme CDX-6114 for the management of phenylketonuria (PKU)
Ingredients

Global partnership to expand pharma biocatalysis uptake

Codexis, Inc. and Porton Pharma Solutions recently announced a strategic collaboration to deploy Codexis’ world-leading biocatalyst technology within Porton’s global custom intermediate and active pharmaceutical ingredients (API) development and manufacturing business. Dr Kevin Robinson caught up with Porton’s Oliver Ju and Codexis’ John Nicols to find our more
Ingredients

Codexis to exhibit at CPhI Worldwide 2017

Codexis is leading the way with powerful biocatalysts that integrate biology and chemistry
Ingredients

Codexis reports loss of US$7m in Q1

Revenue increased by 18% to $8m after significant growth in core biocatalyst R&D revenues and product sales
Manufacturing

Codexis reports 2015 fourth quarter and full year financial results

Financial outlook for 2016 is for another year of growth with revenues in the range of US$46–49m
Ingredients

Codexis files lawsuit against EnzymeWorks and its founder over alleged patent infringement

US developer of biocatalysts also alleges that Junhua (Alex) Tao misappropriated trade secrets
Manufacturing

Codexis and MSD sign multi-year extension of enzyme supply contract

Agreement covers enzyme used in manufacture of sitagliptin
Subscribe now